Arvinas Competitors and Similar CompaniesClear all
Arvinas's competitors and similar companies include Lyell and Foghorn Therapeutics.
 Arvinas Arvinas is a biopharmaceutical company focused on developing protein degradation therapeutics for cancers and other diseases. |  Foghorn Therapeutics Foghorn Therapeutics is a developer of gene therapies for hematologic cancers and solid tumors. | ||
Founding Date | Founding Date N/A | Founding Date 2018 | Founding Date 2016 |
Type | Type Public | Type Public | Type Public |
Tags | |||
Locations | Locations New Haven, US HQ | Locations South San Francisco, US HQ Bothell, US Seattle, US | Locations Cambridge, US HQ Cambridge, US |
Employees | Employees 13329% increase | Employees 188 | Employees 16135% increase |
Valuation ($) | Valuation ($) 1.9 b | Valuation ($) 243.3 m | Valuation ($) 452 m |
Financial | |||
Revenue (est.) | Revenue (est.) $78.5m (FY, 2023) | Revenue (est.) $130k (FY, 2023) | Revenue (est.) $34.2m (FY, 2023) |
Net income | Net income ($367.3m) (FY, 2023) | Net income ($234.6m) (FY, 2023) | Net income ($98.4m) (FY, 2023) |
Funding | |||
Total funding raised | Total funding raised $ 111.6m | Total funding raised N/A | Total funding raised $ 50m |
For sources of this data, please see the company profile
View Company Profiles
Lyell
HQ
South San Francisco, US
Employees
188
Lyell Immunopharma is a T-cell reprogramming company to cure patients with solid tumors.
View companyFoghorn Therapeutics
HQ
Cambridge, US
Employees
161↑ 35% increase
Foghorn Therapeutics is a developer of gene therapies for hematologic cancers and solid tumors.
View company